Skip to main content
Contact Us
Sign Up
Subscriber Sign In
navigation
サイト内検索
COVID-19
COVID-19 Update
Evaluate Vantage COVID-19 Report
COVID-19 Stories from Evaluate Vantage
Evaluate’s Business Continuity Plan
What We Do
Commercial Intelligence
Products
Evaluate Pharma
Evaluate Omnium
Evaluate Epi
Japan Drug Forecasts
Europe Drug Forecasts
Evaluate Custom Solutions
Data Feeds and APIs
Evaluate Vantage
News
Analysis
Policy & Pricing
Data Insights
Events
Medtech
Therapy Areas
Editorial Team
About Evaluate Vantage
Evaluate for Biotech
How We Can Help You
Pharma and Biotech
Medtech
Financial Services
Management Consultancies
Service Providers
Customer Testimonials
Thought Leadership
About Us
Press Releases
Media Coverage
Executive Team
Vision & History
Contact Us
Sign Up for Evaluate Vantage
Talent
Subscriber Sign In
Search
Open configuration options
Search
Vantage
Covid-19
Covid-19 Coverage
Evaluate Vantage COVID-19 Report
News
Snippets
Deals
Trial results
Patents and litigation
Corporate strategy
Analysis
Interviews
Spotlight
Vantage points
Vantage views
Data Insights
M&A
IPO
NME approvals
Quarterly shareprice performance
Venture financing
Vantage data points
Other data
Events
Company events
Conferences
Upcoming events
Medtech
Therapy Areas
About
Editorial team
Somaxon Pharmaceuticals
February 07, 2012
Merck’s new sleep drug has soporific effect on markets
January 06, 2012
Small caps produce clear winners and losers in 2011
November 24, 2011
Intermezzo approval not the end of Transcept thriller
October 04, 2011
Pharmasset continues to lead small cap gainers so far in 2011
September 19, 2011
Transcept and Vivus hoping to buck the trend with another approval chance
July 13, 2011
Intermezzo disappointment another rude awakening for Transcept
January 07, 2011
Comeback stories drive small cap risers in 2010
October 05, 2010
Steady growth the theme for small cap risers after nine months
August 26, 2010
Somaxon seeks to wake up Silenor launch with P&G alarm clock
July 02, 2010
Mixed bag of small cap winners and losers in first half
April 06, 2010
InterMune tops small cap gainers once more in first quarter
Load More
We use cookies on this website. By using this site, you agree that we may store and access cookies on your device.
Find out more.
OK
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up
Latest Reports
May 27, 2021
Evaluate Vantage Biopharma and Venture Capital: A Deep Dive
April 22, 2021
Evaluate Vantage Report: US Approvals Under the Spotlight
Editor's Picks
June 07, 2021
Biogen makes history with Alzheimer’s approval
June 08, 2021
Biogen and the social contract
June 09, 2021
Asco 2021 story roundup
June 03, 2021
Asco 2021 justifies Novartis’s radioligand Vision
May 26, 2021
Roche remains big pharma’s biggest R&D spender
